Company intelligence / Profile preview

CytoSite Bio

Sudbury, Massachusetts, United States

Ownership: Private
Employees: ~10
Development stage: Phase 1

Overview

Preliminary clinical data demonstrates greater than 95% sensitivity and specificity at predicting clinical outcomes for immunotherapy response using their Granzyme B PET imaging technology. Subjects with robust uniform uptake above blood pool in lesions showed treatment response to immune checkpoint inhibitors with continued disease remission during 6-month follow-up.

Therapeutic areas: OncologyImmunology
Modalities: RadiopharmaceuticalsPET imaging agents
Industry: Medical Imaging

Partnerships

Lantheus

Beyond the preview

Go deeper on CytoSite Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CytoSite Bio.

Explore the full profile